A Prospective Cohort Study of Pralsetinib or Anlotinib in the Treatment of Locally Advanced and/or Metastatic Medullary Thyroid Carcinoma With RET Gene Mutations
Not yet recruitingOBSERVATIONAL
Enrollment
40
Participants
Timeline
Start Date
August 1, 2025
Primary Completion Date
February 28, 2026
Study Completion Date
February 28, 2027
Conditions
Medullary Thyroid Cancer (MTC)
All Listed Sponsors
lead
Cancer Institute and Hospital, Chinese Academy of Medical Sciences